Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — Investor Presentation (December 2024)
34 slides from Armata Pharmaceuticals's investor presentation, Dec 19, 2024
Slide 1: Corporate Presentation December 19, 2024
Corporate Presentation December 19, 2024 NYSE American: ARMP
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All s
Slide 3: Armata Highlights
3 Armata Highlights A leading developer of high - purity, pathogen - specific phage therapeutics: • Potential alternative to antibiotics – effective while protecting normal human microbiome • Activity independent of antibiotic resistance, providing critical alternative in setting of increasing MDR w
Slide 4: How Phages Kill Bacteria; Key Advantages of Phage Therapy
4 How Phages Kill Bacteria Key Advantages of Phage Therapy Phages Are a Novel Biologic Anti - Infective with Distinct MOA from Antibiotics and Significant Advantages for the Fight Against AMR PHAGE ADVANTAGES Alternative to broad spectrum antibiotics; Solution to address antibiotic - induced microbi
Slide 5: State of Phage Development and Approval
5 State of Phage Development and Approval PHAGE ADVANTAGES The phage field has focused on compassionate use cases and individualized medicine. What is urgently needed are definitive pivotal trials that clearly address: • Role of phage therapy as an alternative or augmentation of antibiotics to preve
Slide 6: Clinical Pipeline: Multiple Shots on Goal
6 Clinical Pipeline: Multiple Shots on Goal Phage Evaluation via Multi - Centered Randomized - Controlled Clinical Trials SWARM - P.a. NCT04596319 ; diSArm NCT05184764 ; Tail wind NCT05616221 * Department of Defense (DoD) award received through the Medical Technology Enterprise Consortium (MTEC) and
Slide 7: Value-Inflection Milestones Position Both Programs For Pivotal Studies
7 Value - Inflection Milestones Position Both Programs For Pivotal Studies CF: cystic fibrosis; NCFB: non - CF bronchiectasis; SAB: S. aureus bacteremia AP - PA02 CF Ph1b/2a top line data NCFB Ph2 first patient dosed NCFB Ph2 enrollment completion (3Q24) NCFB Ph2 top line data ( 4Q 24) AP - SA02 Pos
Slide 8: Pipeline Addresses Significant Unmet Need & Market Opportunity
8 Pipeline Addresses Significant Unmet Need & Market Opportunity Across Multiple Indications DIVERSIFIED PIPELINE Non-Cystic Fibrosis Bronchiectasis U.S. prevalence (treatable patients)* Key unmet needs for Armata assets Cystic Fibrosis >95,000 >15,000 Total U.S. addressable market size* • Resistanc
Slide 9: Industry-Leading Capabilities in Developing and Manufacturing Phage Therapeutics
9 Armata has Industry - Leading Capabilities in Developing and Manufacturing Phage Therapeutics From Bench to Clinic Discovery • Phage libraries • Pathogen libraries • Synthetic biologists with phage engineering expertise • Computational biology team Preclinical Development • Well - equipped BSL2 la
Slide 10: Recent Achievements Demonstrate Operational Excellence
10 Recent Achievements Demonstrate Operational Excellence WORLD - CLASS CAPABILITIES Perfected engineered host (removal of toxins and prophages) – well positioned for pivotal trial Optimized fermentation and purification leading to increased yields to support commercialization Optimized excipients f
Slide 11: Manufacturing Infrastructure Creates Competitive Advantage and Alternate Revenue Streams
11 Manufacturing Infrastructure Creates Competitive Advantage and Alternate Revenue Streams State of the art cGMP manufacturing facility • 10,000 square foot purpose - built facility • Essential infrastructure for phage production - Two independent production lines with dedicated upstream and downst
Slide 12: Differentiated Phage Manufacturing Approach Creates Significant Clinical Advantages
12 Differentiated Phage Manufacturing Approach Creates Significant Clinical Advantages WORLD - CLASS CAPABILITIES Achieving high purity levels has been a major hurdle for phage drug development • High purity levels creates meaningful clinical differentiators: - Higher dosing - Repetitive IV administ
Slide 13: Leadership and Board of Directors
13 Leadership and Board of Directors Diverse Public Company Drug Development Expertise Deborah Birx, MD CEO Arwa Shurrab Regulatory Strategy and Operations Management Board of Directors Jules Haimovitz Robin Kramer, Chair Todd Peterson, PhD Deborah Birx, MD Odysseas Kostas, MD Joseph Patti, PhD Sara
Slide 14: Strong Relationships with Partners
14 Strong Relationships with Partners With Demonstrated Interest in Supporting Development of Phage Therapy LEADERSHIP AND PARTNERS Armata Partnerships $5M Therapeutics Development Award • Support Ph1b/2a SWARM - P.a. study • All milestones achieved $3M equity investment (4Q21) $21.6M OTA with DoD t
Slide 15: Pseudomonas aeruginosa Program (AP-PA02)
Cystic Fibrosis (CF) Non - CF Bronchiectasis (NCFB) Pseudomonas aeruginosa Program (AP - PA02)
Slide 16: Ph1b/2a SWARM-P.a. Study With Inhaled AP-PA02
16 Ph1b/2a SWARM - P.a. Study With Inhaled AP - PA02: Completed 1Q23 Outpatient Study in CF Adults with Chronic Pulmonary Pseudomonas aeruginosa Infections Study Objectives Key Inclusion Criteria Study Design (25 US sites) ≥10⁴ CFU of Pa per gram of induced sputum at Screening Pa isolates sensitive
Slide 17: Learnings for SWARM-P.a. Ph1b/2a CF Study
17 Learnings for SWARM - P.a. Ph1b/2a CF Study AP - PA02 Well - Tolerated with Consistent Exposures by Dose Learnings Safety and Tolerability for up to 10 days bid dosing • No dose - limiting toxicity • No AEs >Grade 1 attributed to study drug: Grade 1 AEs appear to be intermittent with quick recove
Slide 18: NCFB Phase 2 Trial Top Line Data
* Data are preliminary and remains subject to further review and quality control; findings are subject to change pending complete data that will be presented in the future NCFB Phase 2 Trial Top Line Data*
Slide 19: NCFB Phase 2 Tailwind Study
19 NCFB Phase 2 Tail wind Study: Completed 3Q23 Evaluated AP - PA02 as Monotherapy and in Combination with Inhaled Antibiotics • AP - PA02 nebulized q12h x 10 days • Subjects dosed at home • Started with highest dose from CF study (increased dose 2X after lead in) • Evaluate optimized AP - PA02 expo
Slide 20: Efficacy Analysis Per Statistical Analysis Plan
20 Efficacy Analysis Per Statistical Analysis Plan (10/48 Subjects Not Analyzed ǂ ) Endpoint: Change in CFU at Day 17 Compared to Baseline -4 -2 0 2 4 Copy of B T v P 3.0 Δ C F U ( l o g 1 0 ) 0.2500 Treated Placebo -3 -2 -1 0 1 2 3 Copy of A T v P 3.0 Δ C F U ( l o g 1 0 ) 0.3048 Treated Placebo Co
Slide 21: Post Hoc P. aeruginosa Efficacy Data ITT Population
21 POST HOC P. aeruginosa Efficacy Data ITT Population Analysis - All 48 Subjects * Non - parametric, unpaired t test ** Paired t - Test Significant difference in the treated group between baseline and Days 10, 11, 17, and 24 but not at any timepoint in placebo Change in Pa density from Baseline: Tr
Slide 22: Post Hoc ITT Independent Cohort Analysis
22 POST HOC ITT Independent Cohort Analysis AP - PA02 Alone Is As Effective As AP - PA02 Plus Antibiotics • Small sample size of Cohort B limits meaningful comparison of AP - PA02 alone vs. combination of AP - PA02 with antibiotics N=23 N=15 N=10 * Non - parametric, unpaired t test AP - PA02 Treated
Slide 23: Ph3 NCFB Study Design Considerations
23 Ph3 NCFB Study Design Considerations Evaluation of AP - PA02 Monotherapy as First Approved NCFB Therapeutic Study Objectives / Endpoints Effect of inhaled AP - PA02 monotherapy, administered BID x 48 weeks ** compared to placebo in NCFB chronically infected with P. aeruginosa • Reduction in frequ
Slide 24: Staphylococcus aureus Program (AP-SA02)
Complicated Bacteremia Prosthetic Joint Infection Staphylococcus aureus Program (AP - SA02)
Slide 25: Bacteremia Phase 1b/2a diSArm Study Design
25 Bacteremia Phase 1b/2a “diSArm” Study Design Ph1b (Dose - finding) Enrolls Uncomplicated + Complicated SAB; Ph2a Enrolls Complicated Only Study Endpoints • Phase 1b: Safety and tolerability of multiple intravenous (IV) doses of AP - SA02 • Phase 2a: Clinical Improvement or Response at Day 12, Cli
Slide 26: Bacteremia diSArm Phase 1b/2a: Fully Enrolled
26 Bacteremia diSArm Phase 1b/2a: Fully Enrolled Top - Line Data Expected 1Q2025 • 50 subjects dosed (100%) • Phase 1b: 8 subjects • Phase 2a : 42 subjects • Accelerated enrollment since 3Q23 • Well - tolerated – q6 hour infusion for 5 days • Dose escalated to 2 E11 PFU / 24 h • 28 sites activated (
Slide 27: Early Evidence of AP-SA02 Amplification With Active S. aureus Bacteremia
27 Early Evidence of AP - SA02 Amplification With Active S. aureus Bacteremia* Early Ph2 PK Data Suggests AP - SA02 is Active and Warrants Further Investigation in a Ph3 Trial • Retention of AP - SA02 phage activity from blood samples collected post dosing • The fact that we can find phage means thi
Slide 28: Evidence of AP-SA02 Amplification Upon Dose Escalation
28 0 20 40 60 80 0 2 4 6 8 Copy of persis Time (minutes) P F U / m L ( l o g 1 0 ) Subject G Subject H Subject J Subject U Subject V Subject L Subject P Subject CC Subject S Subject X Subject PP (5E10) Subject TT(5E10) Subject QQ (5e10) Subject OO (5e10) 0 20 40 60 80 0 2 4 6 8 Copy of clearance Tim
Slide 29: Ph3 SAB Study Design Considerations
29 Ph3 SAB Study Design Considerations Non - Inferiority Antibiotic Sparing/Reducing Study for Uncomplicated and Complicated SAB Study Objectives/Endpoints • Primary Objective − Demonstrate non - inferiority of AP - SA02 to antibiotics in uncomplicated SAB − Demonstrate non - inferiority of 2 wks of
Slide 30: Corporate Summary
Corporate Summary
Slide 31: Funding and Capitalization
31 Funding and Capitalization Cash Position • $17.1 million unrestricted cash and cash equivalents at end 3Q24* Financing History • Q1 2020: $25M private placement of common stock and warrants with Innoviva, Inc. • Q1 2021: $20M private placement of common stock and warrants with Innoviva Strategic
Slide 32: Strong Global IP Position Through Pending and Issued Patents
32 Strong Global IP Position Through Pending and Issued Patents 14 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiration dates through 2045 with additional competitive moat due to manufacturing complexity and extensive proprietary process development knowledge P
Slide 33: Grateful to the patients, research team and site investigators
33 Grateful to the patients, the research team and site investigators that make this work possible, and to our funders We are privileged to work across the United States and Australia in nearly 75 sites for the three Phase 2 trials We are effective due to top - notch employees that work at Armata ev
Slide 34: PuARMACEUTICALS
PuARMACEUTICALS OSEFUL @ PRECISE ¢ POWE www.armtapharma.com
Armata Pharmaceuticals — Investor Presentation (December 2024) on 6ix